Education
About Us
Working with TipRanks
Follow Us
Viatris (VTRS)
NASDAQ:VTRS
VTRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.85 - $13.55
Previous CloseN/A
Volume2.11M
Average Volume (3M)9.06M
Market Cap
$12.37B
Enterprise Value$24.57B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$14.46B
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 10, 2025EPS Estimate
0.62Next Dividend Ex-Date
Aug 22, 2025Dividend Yield4.52%
Share Statistics
EPS (TTM)0.62
Shares Outstanding1,165,872,100
10 Day Avg. Volume11,831,818
30 Day Avg. Volume9,063,724
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.99
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda-46.58
Forecast
1Y Price Target
$9.13Price Target Upside-14.11% Downside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
China Segment PerformanceThe China segment showed unexpected strength, delivering 9% operational growth.
Company GuidanceViatris remains confident in achieving full-year guidance and expects results closer to the top end of the range.
Bears Say
EBITDA GuidanceViatris' 4Q update was highlighted by disappointing FY25 EBITDA guidance, coming in 8% below consensus.
Revenue ImpactThe generic Revlimid impact, due to its inclusion on the import ban list, resulted in a $200 million revenue loss at a gross margin exceeding 95%.
Strategic ChallengesThe company still struggles to define its identity in the biopharma ecosystem, reflecting ongoing strategic challenges.
Viatris News
VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was $6.85 and its highest was $13.55 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $12.37B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Nov 10, 2025 which is in 83 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Aug 07, 2025. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.556 by $0.064.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Overvalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 4.52%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.62.
How many shares outstanding does Viatris have?
Viatris has 1,165,872,100 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.62 in its last earnings report, beating expectations of $0.556. Following the earnings report the stock price went up 7.314%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in VTRS
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.13 (-14.11% Downside)
$9.13 (-14.11% Downside)
Blogger Sentiment
Neutral
VTRS Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $219.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.78%
12-Months-Change
Fundamentals
Return on Equity
-19.77%
Trailing 12-Months
Asset Growth
-15.26%
Trailing 12-Months
Company Description
Viatris
Viatris (VTRS) is a global healthcare company formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. The company operates in the pharmaceutical sector, focusing on providing access to medicines across a wide range of therapeutic areas, including infectious diseases, cardiovascular health, diabetes, and oncology. Viatris offers a diverse portfolio of generic and branded medications, over-the-counter products, and biosimilars, aiming to improve patient health outcomes worldwide.
VTRS Company Deck
VTRS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments, such as revenue growth in key regions and pipeline advancements, alongside ongoing challenges, particularly in North America and Japan, and issues with the Indore facility. Despite these challenges, the overall outlook remains optimistic due to the strength of pipeline advancements and strategic initiatives.View all VTRS earnings summariesVTRS Net sales Breakdown
60.77% Developed Markets
15.32% Emerging Markets
14.75% Greater China
9.16% JANZ
VTRS Stock 12 Month Forecast
Average Price Target
$9.13
▼(-14.11% Downside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
0.24% Insiders
26.63% Mutual Funds
18.84% Other Institutional Investors
24.85% Public Companies and Individual Investors